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The efficacy of antiretroviral therapies for human immunodeficiency virus (HIV) infection can be
assessed by studying the trajectory of the changing viral load with treatment time, but estimation of viral
trajectory parameters by using the implicit function form of linear and nonlinear parametric models can
be problematic. Using longitudinal viral load data from a clinical study of HIV-infected patients in
Taiwan, we described the viral trajectories by applying a nonparametric mixed-effects model. We were
then able to compare the efficacies of highly active antiretroviral therapy (HAART) and conventional
therapy by using Young and Bowman’s (1995) test.
Key words: AIDS clinical trial, HIV dynamics, longitudinal data, kernel regression, nonparametric
mixed-effects model, viral load trajectory
roles in clinical research evaluating antiviral
therapies for the acquired immunodeficiency
syndrome (AIDS). Before HIV RNA assays
were developed in mid-1990s, CD4+ cell counts
served as the primary surrogate marker in AIDS
clinical trials. Later, the amount of HIV RNA in
the patient’s plasma (viral load, measured as the
copy number of the viral RNA) was shown to
better predict the clinical outcome (Mellors et
al., 1995; Mellors et al., 1996; Saag et al., 1996),
and thus replaced CD4+ cell counts as the
primary surrogate marker used in most AIDS
clinical trials.
It is, therefore, important to characterize
the trajectory that describes the change in viral
load that occurs during antiviral treatment,
because it is this trajectory that is commonly
used to evaluate the efficacy of the treatment.
For example, if the viral load reduces, we may
infer that the treatment has successfully
suppressed the replication of the virus. The
differences between the viral loads resulting
from different antiviral treatments may be used
to compare the antiviral activities of the
treatments. Appropriate analysis of the viral load

Introduction
Surrogate viral markers, such as the amount of
HIV RNA in the plasma (the amount of HIV
RNA in the patient’s plasma represents the
patient’s viral load), currently play important
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is therefore very important in HIV/AIDS drug
development. In general, it is believed that the
replication of the virus is suppressed at the
beginning of an antiviral treatment, but recovery
of the virus (called rebound) can occur in later
stages of treatment, because of drug resistance
or treatment failure. Some parametric models
have been developed to describe the progression
of AIDS phenomenologically; among the best
known of these models are the exponential
models (Ho et al., 1995; Wei et al., 1995). More
recently, biomathematicians and biologists have
proposed a variety of complicated models that
include the use of differential equations. The use
of these models has led to a deeper
understanding of the pathogenesis of AIDS (e.g.,
Perelson & Nelson, 1999; Wu and Ding, 1999).
In recent years, the necessity for
appropriate models has gained more importance
with the widespread use of highly active
antiretroviral therapy (HAART) to treat
HIV/AIDS (Ghani et al., 2003). Numerous
studies have shown that HAART is effective in
extending the time taken from the diagnosis of
HIV-infection to AIDS or death in HIV-infected
patients (e.g., Detels et al., 1998; Tassie et al.,
2002) as well as reducing the likelihood of
perinatal HIV transmission (Cooper et al., 2002).
However,
in many
clinical practices,
combination antiviral therapy has failed to
completely and durably suppress HIV
replication (e.g., Deeks et al., 1999).
To determine the efficacy of treatments
in suppressing HIV replication in patients, the
present study focuses on the following
questions: (i) Given longitudinal viral load data,
how can one identify a common feature of the
antiviral activities of each treatment? (ii) How
can we compare the antiviral efficacies of two
different treatments? If we can answer question
(ii), we may be able to demonstrate that the
better treatment should be evaluated in a largescale clinical study. However, it may be
difficult to answer these questions by using
existing parametric or semi-parametric methods.
To sufficiently consider all of the information
available from the observations, and to avoid the
misspecification of parametric modeling, we
will use a nonparametric mixed-effects model to
analyze the longitudinal viral load data, and we
will incorporate the local linear approximation

technique developed by Wu and Zhang (2002).
The test statistic proposed by Young and
Bowman (1995) will then be used to answer
question (ii).
The remainder of this paper is organized as
follows. In Section 2, we give details of the
proposed model, with the method of estimation,
and use the test statistic of Young and Bowman
(1995) to determine whether there is a difference
between the effects of two treatments. In Section
3, we illustrate the use of the proposed
methodology with longitudinal viral load data
from 30 HIV-infected patients treated with
HAART alone and another 30 patients treated
with monotherapy or dual therapy. Some
discussion is given in Section 4.
Methodology
Nonparametric Models and Estimation Methods
We fit the viral load trajectory data of
HIV-infected patients receiving a treatment by
using a nonparametric mixed-effects (NPME)
model:

y i (t ) = log10 {Vi (t )} = η (t ) + vi (t ) + ε i (t ) ,
i = 1,2,..., n
(2.1)
where Vi (t ) is the number of copies of HIV-1
RNA per mL of plasma at treatment time t for
the ith patient and y i (t ) is the corresponding

value in log10 scale; η (t ) is the population mean
function, also called the fixed-effects or
population curve; vi (t ) are individual curve

variations from the population curve η (t ) and
these variations are called random-effects
curves; and ε i (t ) are measurement errors. We

assume that vi (t ) and ε i (t ) are independent in
which vi (t ) can be considered as realizations of
a mean 0 process with a covariance function γ(s,
t) = E( vi (s ) vi (t ) ), and εi(t) can be considered
as realizations of an uncorrelated mean 0 process
2

with variance σ (t ) . The population curve
η (t ) reflects the overall trend or progress of the
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treatment process in an HIV-infected population
and, hence, can provide an important index of
the population’s response to a drug or treatment
in a clinical or biomedical study, so in this paper
we are mainly interested in estimating η (t ) . In
addition,
an
individual
curve
s i (t ) = η (t ) + vi (t ) can
represent
an
individual’s response to a treatment in a study,
so a good estimate of s i (t ) would help the
investigator to make better decisions about an
individual’s treatment management and would
enable us to classify subjects on the basis of
individual response curves. Similar models have
been proposed by Shi et al. (1996) and Zeger
and Diggle (1994) to describe CD4+ cell counts.
Let t gij , j = 1,2,..., n gi , be the design
time points for the ith individual in treatment
group g. Then, NPME model (2.1) becomes
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X gij = (1, (t gij − t )) , β g = ( η g (t ) , η ′g (t ) )T,
T

and b gi = ( v gi (t ) , v ′gi (t ) )T.
Consequently, the NPME model (2.2) can be
approximated by the following model:

y gij = X gij ( β g + b gi ) + ε gij , j = 1,2,..., n gi ;
T

i = 1,2,..., n g ; g = 1,2

(2.3)

which is called a LME model. Note that, for
simplicity of notation,

y gij = y gi (t gij ) , ε gij = ε gi (t gij ) , ε gi =
(ε gi1 ,..., ε gin gi ) ∼ N(0, Σ gi ), and b gi ∼ N(0, Dg)
T

for Σ gi = E( ε gi ε gi ) and Dg = E( b gi b gi ).
T

T

To estimate η g (t ) and v gi (t ) , which are

y gi (t gij ) = η g (t gij ) + v gi (t gij ) + ε gi (t gij ) ,

the first element of β g and b gi , respectively,

j = 1,2,..., n gi ; i = 1,2,..., n g ; g = 1,2
(2.2)

under the standard normality assumptions
for b gi , we can minimize the following objective

Here, ng is the number of subjects in treatment
group g, and ngi is the number of measurements
made from subject i in treatment group g. We
now
wish
to
estimate
η g (t ) and

function:

v gi (t ) simultaneously, via a local approximation

( y gi − X gi ( β g + b gi )) + b gi D g b gi +

of the NPME model (2.2), by using the local
linear mixed-effects model approach of Wu and
Zhang (2002), which combines linear mixedeffects (LME) models (Laird & Ware, 1982) and
local polynomial techniques (Fan & Gijbels,
1996). For this purpose, we assume the existence
of the second derivatives of η g (t ) and v gi (t ) at
t, which are then approximated locally by a
polynomial of order 2 as follows:

η g (t gij ) ≈ η g (t ) + η ′g (t )(t gih − t ) ≡ X gij β g
T

and

ng

∑{( y
i =1

1/ 2

−1

1/ 2

− X gi ( β g + b gi )) K giλ Σ gi K giλ
T

gi

−1

T

log | Σ gi |}
where
T

y gi = ( y gi1 ,..., y gin gi ) ; X gi = ( X gi1 ,..., X gingi )

T

; K giλ =diag{ K λ (t gij − t ),..., K λ (t gin gi − t ) }
is the kernel weight of the residual term for Kλ(.)
= K(. /λ)/λ, in which K(.) is a kernel function; λ
is a bandwidth selected by a leave-one-subjectout cross-validation approach (Wu & Zhang,
T

−1

2002); and the term b gi D g b gi is a penalty

v gi (t gij ) ≈ v gi (t gij ) + v ′gi (t )(t gij − t ) ≡ X gij b gi

term to account for the random effects b gi ,

where

taking between-subject variation into account.

T
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Thus, for given Σ gi and D g , the resulting
estimators can be obtained as follows:

βˆ g =
ng

(∑ X gi Ω gi X gi )
T

−1

i =1

ng

TS

(∑ X gi Ω gi y gi )
T

2

=∑∑

i =1

−1

−1

{ηˆ g (t gj ) − ηˆ c (t gj )}

σˆ

g =1 j∈Tg

T
1/ 2
−1
1/ 2
bˆ gi = ( X gi K giλ Σ gi K giλ X gi +

Dg )

curves is statistically significant. To compare the
effects of two treatments, we apply the
following test statistic (Young & Bowman,
1995):
2

(2.5)

2

where Tg = {all distinct times t gi in treatment

T
1/ 2
−1
1/ 2
X gi K giλ Σ gi K giλ ( y gi − X gi βˆ g )

g} and

(2.4)

σˆ = ∑ g =1 ∑i =1 (n gi − 1)σˆ gi /(n − ∑ g =1 n g ) is
2

where
1/ 2

1/ 2

T

1/ 2

Ω gi = K giλ ( K giλ X gi D g X gi K giλ + Σ gi )

−1

1/ 2

K giλ . As a result, the estimators of η g (t )

error with n =

The unknown variance-covariance parameters in
Dg and Σ gi can be estimated by using maximum
or restricted maximum likelihood, implemented
by using the EM algorithm or the NewtonRaphson method (Davidian & Giltinan, 1995;
Vonesh & Chinchilli, 1996).
Of particular interest are the comparative
effects of the two treatments. Therefore, we need
to compare the equality of the two population
curves η1 (t ) and η 2 (t ) . To do this, we fit the
model η c (t ) + v cgi (t ) to all data, where η c (t ) is

the fixed-effects (population) curve for the data
and vcgi (t ) are random-effects curves that
deviate from η c (t ) . As is done when estimating

η g (t ) and v gi (t ) , we can use the local linear
approximation approach of Wu and Zhang
(2002)
to
obtain
the
estimators,
ηˆ c (t ) and vˆcgi (t ) , of η c (t ) and vcgi (t ) .
Our main concern is how to justify that
the difference between the two population

2

∑ ∑
2

ng

g =1

i =1

2

n gi ; σˆ gi are obtained

by using the first-order difference approach
proposed by Rice (1984), as follows:
2

0) b̂ gi .

2

ng

an estimator of the variance of the measurement

and

v gi (t ) are ηˆ g (t ) = (1, 0) βˆ g and vˆ gi (t ) = (1,

2

σˆ gi =

1
2(n gi

n gi −1

∑(y
− 1)
j =1

2

gi[ j +1]

− y gi[ k ] ) ,

i = 1,2,..., n g ; g = 1,2
If the two population curves are equal; that is,
under the null hypothesis H0: η1(t) = η2(t), the
distribution of the test statistic TS in (2.5) is then
approximated by aχ2(b) + c, where χ2(b) is a
chi-squared distribution with b degrees of
freedom. Moreover, a, b, and c are constants
such that the mean, variance, and skewness of
aχ2(b) + c are equal to the corresponding
quantities of the test statistic TS, which can be
calculated directly. The distribution of aχ2(b) +
c is then used to calculate the p-value. The
standard error of the difference between the
estimates for the two population curves can be
computed as
sediff(t) = se{ ηˆ1 (t ) − ηˆ 2 (t ) } =

2

2

se1 ( t ) + se 2 ( t )

where se1(t) = se{ ηˆ1 (t ) } and se2(t) = se{ ηˆ 2 (t ) }
are the standard errors of the estimates of the
population curves, respectively. A reference
band whose width is centered at the average of
the two estimated curves ±2 × sediff(t) can be
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used to see how much difference there is
between the two treatment groups (Young and
Bowman, 1995). Note that, theoretically we
should consider correlation when using the
approach of Young and Bowman (1995), but we
do not just because of mathematical simplicity.
Ignoring the correlation may lose some
efficiency, however, as you will see, for the reallife data analysis given in the next section there
is significant difference between the treatment
effects of the two groups even using independent
structure. Considering correlation may increase
power but seems unnecessary.
Results
The Analysis of Longitudinal Viral Load Data
In this section, we illustrate the practical use of
the proposed methodology with longitudinal
viral load data from HIV-infected patients. The
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data set we are using includes the longitudinal
viral load data obtained from 30 HIV-infected
patients who received monotherapy or dual
therapy and 30 HIV-infected patients who
received HAART in several hospitals in Taipei,
Taiwan, between 1997 and 2002. These data are
subsets of data from a much larger cohort data of
1,195 HIV-infected patients in Taipei. Among
the 1,195 HIV-infected patients, most of them
received diverse treatments, so, to ensure the
validity of the comparison, we chose to use data
from the patients treated with HAART who had
never been given any other treatment regimen
and non-HAART patients who had never been
treated with HAART. Treatment durations
varied, because patients began receiving
treatment at different times during the study
period. Figure 1 presents scatter plots of viral
load (in log10 scale) against treatment durations
for the HIV-1-positive patients.

Figure 1: Scatter plot of viral load (log10 of copy number of HIV RNA in plasma) versus
duration of treatment with HAART (left) or non-HAART (right).
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After excluding missing data, we have
208 complete viral load observations in the
HAART group, of which 108 have a value less
than 400; and we have 164 complete viral load
observations in the non-HAART group, of
which 69 have a value less than 400. If we use
the criterion that a treatment is considered
successful in its antiviral effect when the viral
load is below 400, the success rates in the
HAART and non-HAART groups are 51.9% and
42.1%, respectively.
For data analysis, we used the quartic
kernel, K(u) = (15/16)(1 – u2)2I(|u| ≤1). The
estimates of the two population curves are
depicted in Figure 2. From Figure 2, we can see
that the estimates of the two population curves
have different patterns although both decrease at
the beginning of treatment. The estimated curve
for the HAART group shows that the viral load
is maintained at a constant level until the end of
the treatment, whereas that for the non-HAART
group shows that the viral load decreases sharply
during the first 480 days, reaching its lowest
point on day 480. However, after 480 days, the

viral load increases, remains constant for a short
time, and increases again at the end of the
treatment.
A Chi-squared test for the success rates
of the two treatments gives a p-value of 0.07. It
is hard to say that there is a significant
difference between the effects of the two
treatments, although the success rate in the
HAART group is greater than that in the nonHAART group. Therefore, to look more closely
at the difference between the effects of the two
treatments, we use the principle described in
Section 2. The p-value obtained by using this
method is less than 10-4, which indicates that the
two population curves for each treatment are
substantially different. To confirm this
conclusion, we obtained a range of reference
values and plotted them with our viral load
trajectory estimates in Figure 2. The two
estimated population curves deviate from the
reference band, and the efficacy of the HAART
is seen to be almost significantly superior to that
of the conventional therapy that does not include
HAART.

Figure 2. Estimate of two population curves.
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Discussion
To determine the efficacy of antiviral treatments
by using longitudinal viral load data, we applied
nonparametric mixed-effects models to estimate
the patterns of the viral trajectories in the two
sampled populations. This approach avoids
misspecification and, thus, the occurrence of an
artificial bias. By combining the betweensubject and within-subject information, the
models we have proposed can parsimoniously
capture the features of viral response to an
antiviral therapy, such that the estimated curve is
able to show common features of the antiviral
activity.
In implementing the estimation of
population curves, we used local linear
regression and the
bandwidth selection
method proposed by Wu and Zhang (2002) to
select the bandwidth. Besides the local linear
methods applied in this article, the method of
regression splines may also be implemented
for parameter estimation. The approach of
regression splines transforms the models to
standard linear mixed-effects models and is easy
to implement by using existing software such
as SAS and SPLUS.
The result of our illustrative example
indicates that HAART has effects that are
significantly different from those of treatment
that did not include HAART. At the beginning
of treatment, non-HAART has strong antiviral
activity, which is lacking with HAART.
However, during the course of the treatment,
the superiority of non-HAART lessens, and this
therapy ultimately
fails, whereas HAART
maintains a constant effect throughout treatment.
This maintenance of
the viral load at a
constant level confirms previous findings and is
preferable to the fluctuation of load resulting
from non-HAART. This result confirms that
HAART is worth continuing,
despite its
inability to suppress viral replication completely
(Deeks & Martin 2001).
Finally, the reference band covers a
wider range of viral loads at the end of
treatment, despite the increasing difference
between the two estimated curves. This is not
surprising because of the smaller sample size
resulting from a shorter treatment duration for
some patients at that time.
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